Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab

Trial Profile

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2018

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STARDUST
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 03 Oct 2018 Planned End Date changed from 25 Apr 2021 to 24 Jul 2021.
    • 31 Aug 2018 Biomarkers information updated
    • 18 Apr 2018 Planned End Date changed from 28 Feb 2021 to 25 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top